Amylyx Pharmaceuticals fetches $5 mln Series A
Cambridge, Massachusetts-based Amylyx Pharmaceuticals Inc, a developer of treatments for neurodegenerative diseases, has closed $5 million in Series A financing. Morningside Venture led the round with participation from other investors that included ALS Investment Fund and former Genzyme CEO Henri Termeer.
23 August 2016•1 min read
